Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Potency of Allogenic MSCs for Non Union Fracture and Long Bone Defect
NCT02307435Phase 1Unknown
- Sponsor
- Universitas Indonesia
- Start
- Aug 2014
- Primary completion
- Dec 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogenic mesenchymal stem cells in non-union fracture and Long bone defect, sponsored by Universitas Indonesia. Primary endpoint: Cell viability at 3 months. Status: unknown.
02
Drugs
allogenic mesenchymal stem cells
03
Conditions
non-union fractureLong bone defect
Beyond the preview
Go deeper on NCT02307435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02307435.